Navigating adalimumab biosimilars: an expert opinion

The patent expiry of Humira(®) in 2018 opened up the current European market to eight adalimumab biosimilars – (in alphabetical order) Amgevita(®), Amsparity(®), Hulio(®), Hukyndra(®), Hyrimoz(®), Idacio(®), Imraldi(®) and Yuflyma(®) – for the treatment of various immune and inflammatory conditions....

Descripción completa

Detalles Bibliográficos
Autores principales: Abitbol, Vered, Benkhalifa, Salim, Habauzit, Caroline, Marotte, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690439/
https://www.ncbi.nlm.nih.gov/pubmed/37855223
http://dx.doi.org/10.57264/cer-2023-0117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690439/
https://www.ncbi.nlm.nih.gov/pubmed/37855223
http://dx.doi.org/10.57264/cer-2023-0117

Ejemplares similares